Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node–Positive Gastric Cancer Treated with Different Adjuvant Protocols
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to compare prognostic differentiation performances of the 7th and the 8th edition of American Joint Committee on Cancer (AJCC) staging system for gastric cancer (GC) patients. Materials and Methods A total of 1,633 GC patients who underwent curative D2 resection followed by adjuvant chemotherapy alone (CA) or concurrent chemo-radiotherapy (CCRT) from 2004 to 2013 were included. Concordance index (c-index) was applied to compare the discriminatory ability. Results In the 8th edition, migration of stage was detected in 248 patients (15.2%). Among them, 121 patients were up-staged while 127 patients were down-staged. Overall, there was no statistically significant difference in the discriminatory ability between the 7th and 8th editions. The new edition of staging system, however, showed a trend of better prognostic performance not only in recurrence-free survival (c-index=0.734; 95% confidence interval [CI], 0.706 to 0.762 in the 7th edition vs. c-index=0.740; 95% CI, 0.712 to 0.768 in the 8th edition; p=0.14), but also in overall survival (c-index=0.717; 95% CI, 0.688 to 0.745 in the 7th edition vs. c-index=0.722; 95% CI, 0.694 to 0.751 in the 8th edition; p=0.19), especially in stage III. This finding was repeated in the subgroup analysis regardless of adjuvant CA or CCRT. Conclusion Generally, the 8th edition of AJCC staging system had failed to show a superior discriminatory ability for curatively D2 resected GC patients than the 7th edition, although there was a trend of better prognostic performance of the new edition, regardless of adjuvant treatment method.
Abstract
Purpose The purpose of this study was to compare prognostic differentiation performances of the 7th and the 8th edition of American Joint Committee on Cancer (AJCC) staging system for gastric cancer (GC) patients. Materials and Methods A total of 1,633 GC patients who underwent curative D2 resection followed by adjuvant chemotherapy alone (CA) or concurrent chemo-radiotherapy (CCRT) from 2004 to 2013 were included. Concordance index (c-index) was applied to compare the discriminatory ability. Results In the 8th edition, migration of stage was detected in 248 patients (15.2%). Among them, 121 patients were up-staged while 127 patients were down-staged. Overall, there was no statistically significant difference in the discriminatory ability between the 7th and 8th editions. The new edition of staging system, however, showed a trend of better prognostic performance not only in recurrence-free survival (c-index=0.734; 95% confidence interval [CI], 0.706 to 0.762 in the 7th edition vs. c-index=0.740; 95% CI, 0.712 to 0.768 in the 8th edition; p=0.14), but also in overall survival (c-index=0.717; 95% CI, 0.688 to 0.745 in the 7th edition vs. c-index=0.722; 95% CI, 0.694 to 0.751 in the 8th edition; p=0.19), especially in stage III. This finding was repeated in the subgroup analysis regardless of adjuvant CA or CCRT. Conclusion Generally, the 8th edition of AJCC staging system had failed to show a superior discriminatory ability for curatively D2 resected GC patients than the 7th edition, although there was a trend of better prognostic performance of the new edition, regardless of adjuvant treatment method.
참고문헌 (30)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015", Cancer Research and Treatment, 50(2), pp.303~316 (2018), 대한암학회
- Global Burden of Disease Cancer Collaboration, "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted lifeyears for 32 cancer groups, 1990 to 2015 : a systematic analysis for the global burden of disease study", JAMA Oncol, 3, pp.524~548 (2017)
- Torre LA, "Global cancer incidence and mortality rates and trends : an update", Cancer Epidemiol Biomarkers Prev, 25, pp.16~27 (2016)
- Oh Kyoung Kwon, "Validation of the 7th AJCC", UICC staging system for gastric cancer and a proposal for a new TNM system based on a prognostic score: a retrospective multicenter study, 2016, pp.91(6), 295~302[DOI]
- Shu P, "The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III", BMC Cancer, 17, pp.238~ (2017)
- In H, "The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer(AJCC)staging", Gastric Cancer, 21, pp.1~9 (2018)
- He X, "Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis", Gastric Cancer, 21, pp.391~400 (2018)
- 김성근, "Comparison of the Differences in Survival Rates between the 7th and 8th Editions of the AJCC TNM Staging System for Gastric Adenocarcinoma: a Single-Institution Study of 5,507 Patients in Korea", Journal of Gastric Cancer, 17(3), pp.212~219 (2017), 대한위암학회[DOI]
- Li Z, "ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system", Gastric Cancer, 21, pp.977~987 (2018)
- Lu J, "The effectiveness of the 8th American Joint Committee on Cancer TNM classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 7th and 8th editions", Eur J Surg Oncol, 43, pp.2349~2356 (2017)
- Lu J, "Is the 8th edition of the AJCC TNM staging system sufficiently reasonable for all patients with noncardia gastric cancer? A 12,549-patient international database study", Ann Surg Oncol, 25, pp.2002~2011 (2018)
- Yu JI, "Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer", Radiother Oncol, 129, pp.306~312 (2018)
- Lee J, "Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection : the ARTIST trial", J Clin Oncol, 30, pp.268~273 (2012)
- Macdonald JS, "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction", N Engl J Med, 345, pp.725~730 (2001)
- Smalley SR, "Updated analysis of SWOG-directed intergroup study 0116 : a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection", J Clin Oncol, 30, pp.2327~2333 (2012)
- Bang YJ, "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC) : a phase 3 open-label, randomised controlled trial", Lancet, 379, pp.315~321 (2012)
- Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)
- Harrell FE Jr, "Regression modelling strategies for improved prognostic prediction", Stat Med, 3, pp.143~152 (1984)
- Astler VB, "The prognostic significance of direct extension of carcinoma of the colon and rectum", Ann Surg, 139, pp.846~852 (1954)
- Aurello P, "Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature", Am Surg, 73, pp.359~366 (2007)
- Chen XL, "Prognostic significance and the role in TNM stage of extranodal metastasis within regional lymph nodes station in gastric carcinoma", Oncotarget, 7, pp.67047~67060 (2016)
- 유정일, "Prognostic Index for Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Treated with Radiation Therapy", Journal of Korean Medical Science, 26(8), pp.1014~1022 (2011), 대한의학회
- Amin MB, "AJCC cancer staing manual" (2017), Springer
- Shim JH, "Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis", Ann Surg Oncol, 21, pp.2332~2339 (2014)
- GASTRIC (Global Advanced, "Adjuvant Stomach Tumor Research International Collaboration) Group", Benefit of adjuvant chemotherapy for resectable gastric cancer : a meta-analysis, 2010, pp.303, 1729~1737
- Songun I, "Surgical treatment of gastric cancer : 15-year follow-up results of the randomised nationwide Dutch D1D2 trial", Lancet Oncol, 11, pp.439~449 (2010)
- Ohri N, "Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis", Int J Radiat Oncol Biol Phys, 86, pp.330~335 (2013)
- Dai Q, "Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer : a meta-analysis of randomized controlled trials", J Surg Oncol, 111, pp.277~284 (2015)
- Park SH, "Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer : final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses", J Clin Oncol, 33, pp.3130~3136 (2015)
- Yu JI, "Effects of adjuvant radiotherapy on completely resected gastric cancer : a radiation oncologist's view of the ARTIST randomized phase III trial", Radiother Oncol, 117, pp.171~177 (2015)